New report outlines innovative state strategies for managing high-cost Medicaid prescription drugs.
Magellan Rx Management, the full-service pharmacy benefits management division of Magellan Health, Inc., today released its fourth annual Medicaid Pharmacy Trend Report, developed through in-depth data analysis and supported by Magellan’s experience in managing fee-for-service (FFS) Medicaid pharmacy programs.
The report outlines emerging and innovative state strategies for managing high-cost Medicaid prescription drugs. The report also includes a forecast of the top key conditions in Medicaid along with a pipeline analysis of drugs expected to impact the Medicaid program.
Key findings in this year’s report include:
Related:Generics of Older Drugs Could Have Saved Medicare Billions, Study Says
“The Medicaid Pharmacy Trend Report is an effective tool in providing states with data and solutions to better manage cost trends and improve budget predictability for their Medicaid FFS pharmacy benefit management program,” says Doug Brown, vice president and chief strategy officer, government markets, Magellan Health. “The report examines drug classes with the largest effect on Medicaid net spend, cost-saving opportunities, and a detailed look at how recent legislative and state program innovation has and will affect the Medicaid program.”